Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.
Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.
Sells the pump system to hospitals and gets recurring revenue from single-use IV sets used with every pump, so the installed base of pumps matters. Its pumps are designed to work inside the magnetic field of an MRI scanner, where ordinary electric pumps cannot be used.
Moat: narrow (IP / patents, regulatory licence). One of few makers of infusion pumps safe to use inside the MRI's magnetic field, a narrow regulated niche.
Headquarters: Winter Springs, Florida · Founded: 1992 · Employees: 166
Size IRadimed (IRMD) is a United States Health Care company (Medical Specialties) with a market value of $1.05B, the 2199th largest of 3,085 United States companies the cockpit tracks. Shares closed at $82.31 on 18 Nov 2026.
Performance Over six months the shares fell 8.9%, against -6.8% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 11.0% over the last twelve months (peer median +10.0%); the operating margin is 32.3% (peer median 11.8%).
Valuation It trades at 34.3× forward earnings against a peer median of 18.4× (2nd most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 43.2 points above its cost of capital (9.6% WACC).
Short interest Short interest is 4.6% of the free float (30 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $89.3M | $83.8M | $73.2M | $65.6M | $53.3M |
| Revenue growth | — | +14% | +12% | +23% | — |
| Gross profit | $67.5M | $64.3M | $56.3M | $50.2M | $41.3M |
| EBITDA | $30.5M | $27.3M | $22.8M | $20.8M | $16.3M |
| Net income | $24.0M | $22.5M | $19.2M | $17.2M | $12.8M |
| Free cash flow | $26.1M | $17.2M | $17.6M | $6.02M | $9.22M |
| Capital expenditure | $1.54M | $8.42M | $8.82M | $8.01M | $1.87M |
| Total debt | $0 | $0 | $154,688 | $2.04M | $2.21M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| IRadimed IRMD | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Koninklijke Philips PHIA.AS | $29.0B | +17% | -1% | 10% | 16.4× | 5.9% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -5.1% | 10th lowest of 21 |
| 6-month return | -8.9% | -6.8% | 10th lowest of 20 |
| Distance from 52-week high | -23.7% | -29.4% | 6th highest of 21 |
| Revenue growth (TTM) | +11.0% | +10.0% | 9th highest of 19 |
| Operating margin | 32.3% | 11.8% | 5th highest of 20 |
| Forward P/E | 34.3× | 18.4× | 2nd most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 18.5% | 6.9% | 3rd most demanding of 14 |
| Growth delivered (Del g) | +21.5% | +9.9% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | -3.0 pp | -2.2 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +43.2 pp | +1.5 pp | highest of 19 |
| EV / EBITDA | 32.4× | 8.7× | most expensive of 8 |
| Net debt / EBITDA | -2.1× | 0.2× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |